Skip to content

What insurance covers Wegovy, Zepbound and other GLP-1 medicines?

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

What insurance covers Wegovy depends on your plan and your employer. In the published policies of 11 payers, Wegovy and Zepbound are covered for weight loss only where the plan or employer includes that benefit, and almost always with prior authorization (the plan's approval before it pays). Some payers, such as Blue Cross Blue Shield of Massachusetts, exclude them as standard. Ozempic and Mounjaro are covered for type 2 diabetes.

Source: Federal Register

Key takeaways

  • Ask first whether your plan includes weight-loss drugs at all. Often your employer decides that.
  • If the benefit is there, expect prior authorization. Your prescriber's office files it, not you.
  • Read the reason on any denial. Missing documents can be fixed, but an appeal can't add a benefit your plan lacks.
  • Before a prescription is written, ask your plan which form of the drug is on its list.
  • If a commercial plan covers the drug, a savings card can lower a Wegovy fill to as little as $25.

Whether your insurance pays for a GLP-1 medicine comes down to three questions, in this order. Does your plan include the benefit at all? Do you meet the plan’s written criteria? Is the request for the form and the use the plan covers? This guide answers each one using the published policies of 11 payers (insurers and other programs that pay for medicines), each one quoted in the sources at the foot of the page. Where a payer’s document doesn’t say something, we tell you.

No two plans are the same, even within one insurer. Treat this page as a guide to what payers publish, and treat your own plan document as the final word.

Does commercial insurance cover GLP-1s for weight loss?

Sometimes, and the deciding factor is often your employer, not you. The documents we hold say this in several ways:

  • UnitedHealthcare describes its weight-loss drug coverage as “an optional program that is put in place for clients or businesses that have elected to cover weight loss products.”
  • Blue Cross Blue Shield of Massachusetts excludes Wegovy, Saxenda and Zepbound as each plan renews on or after January 1, 2026. Employer groups with more than 100 employees can add the coverage for an additional cost.
  • Blue Cross Blue Shield of Michigan doesn’t cover GLP-1 drugs used for weight loss for commercial members of fully insured large groups and some self-funded groups.
  • Highmark’s criteria begin with the words “When a benefit,” meaning they apply only to plans that include the anti-obesity benefit.
  • Kaiser Permanente Northwest covers Wegovy injection and Zepbound for weight loss only for members with coverage for medications used to treat weight loss. Others pay the member cash price.
  • Cigna’s policies note that an individual benefit plan can still exclude the drug, and that the plan document overrides the policy.
  • CVS Caremark, a pharmacy benefit manager, describes its formulary (covered drug list) changes as being for plan sponsors who elect to provide coverage.

So your first call is about the benefit. If it isn’t in your plan, no amount of clinical documentation creates it.

What do the published policies commonly require?

Where the benefit exists, the criteria follow a familiar pattern. The details differ by payer, and the differences are big enough to change the outcome.

A BMI threshold

Cigna, UnitedHealthcare, FEP Blue and Kaiser Permanente Northwest use a BMI of 30 or more, or 27 or more with a weight-related condition. Aetna’s policy 6450-C is a “BMI 35” version: adults need a baseline BMI of 35 or more. Highmark’s Enhanced policy asks for a baseline BMI of 40 or more plus specified obesity-related conditions.

Notice the word “baseline.” Several policies judge your BMI as it was before treatment, and renewals are measured against that starting weight.

Evidence of a lifestyle or weight program

Aetna asks for at least 6 months in a “comprehensive weight management program” before the drug. Cigna asks for at least 3 months of behavioral modification and dietary restriction. Highmark asks for at least 6 months of healthy dietary changes and increased physical activity. FEP Blue asks for participation in a “comprehensive weight management program.” UnitedHealthcare asks that the drug be used alongside lifestyle modification.

Age, and no doubling up

Adult criteria start at 18. Some policies also cover adolescents for certain drugs: FEP Blue and UnitedHealthcare cover Wegovy injection from age 12. FEP Blue doesn’t allow use together with another GLP-1 drug, and Highmark’s criteria say the same.

The prior authorization checklist turns these criteria into a list you can take to your prescriber.

What is prior authorization, and who files it?

Prior authorization is the plan’s approval before it pays. Your prescriber’s office files it, not you. Nearly every record we hold for Wegovy, Zepbound, Saxenda and Foundayo carries a prior authorization requirement, and FEP Blue calls the same process “prior approval.”

Your part is to make the file easy to approve. Have these ready: a documented baseline weight and BMI, the dates of any weight program, the conditions that count toward a lower BMI threshold, and the medicines you’ve already tried.

What is step therapy?

Step therapy means the plan wants another treatment tried first. It shows up in our records in four forms:

  • Older medicines first. Kaiser Permanente Northwest requires a failed 3-month trial of at least two older weight-loss medicines before Wegovy. FEP Blue requires an inadequate response, intolerance or contraindication (a medical reason not to take it) to at least two oral weight-management medicines before Zepbound.
  • A preferred GLP-1 first. Highmark makes Zepbound the plan-preferred drug, so Wegovy, Saxenda and Foundayo need a documented intolerance or contraindication to Zepbound. Kaiser Permanente Northwest runs the other way: Zepbound comes after at least 6 months of semaglutide.
  • A generic first. On Cigna employer plans, brand Saxenda requires that generic liraglutide was tried first.
  • Diabetes drugs. Blue Cross Blue Shield of Michigan lists Ozempic and Mounjaro with step therapy and a quantity limit.

The preferred drug differs from payer to payer, which is why a friend’s experience with another insurer tells you little about yours.

Does insurance cover Ozempic or Mounjaro for weight loss?

In the records we hold, no. Ozempic and Mounjaro are covered as type 2 diabetes medicines. Cigna’s employer-plan policy approves them with a documented diagnosis of type 2 diabetes and lists weight loss without type 2 diabetes as a use that isn’t covered. Blue Cross Blue Shield of Massachusetts requires prior authorization including a documented type 2 diabetes diagnosis. TRICARE covers them to treat type 2 diabetes. Anthem’s California Medi-Cal notice keeps them on the drug list with a type 2 diabetes diagnosis restriction.

Each brand has its own label and approved uses. The Ozempic and Mounjaro guides explain what each is approved for, and the Wegovy and Zepbound guides do the same for the weight-management brands.

Does the form of the drug matter?

Yes, more than most people expect. Blue Cross Blue Shield of Michigan lists the Zepbound auto-injector as a preferred brand and the Zepbound KwikPen as not covered. It also lists Wegovy injection as preferred and Wegovy tablets as not covered. UnitedHealthcare’s document says Wegovy tablets are typically excluded from coverage. Aetna’s policy applies to Zepbound pens and says vials and KwikPens are handled outside it, through the LillyDirect manufacturer program.

Before a prescription is written, ask the plan which form is on its list. The pen, vial or pill comparison explains the forms.

Are other uses covered when weight loss is not?

Often, yes. Several policies have separate criteria for approved uses beyond weight management. Aetna, Cigna and UnitedHealthcare each have a route for Wegovy for cardiovascular risk reduction in people with established cardiovascular disease, and for MASH. Aetna, Cigna and UnitedHealthcare also cover Zepbound for moderate to severe obstructive sleep apnea. Even Anthem’s Medi-Cal notice, which ends weight-loss coverage, says prior authorization requests are still considered for Wegovy for MASH or cardiovascular disease and for Zepbound for obstructive sleep apnea.

Your prescriber judges whether one of these applies. If it does, the request should name that use.

How long does an approval last?

Not long at first. First approvals in our records range from 4 months to 8 months depending on the payer and the drug, and renewals usually run 12 months. Renewal for weight loss depends on a documented minimum loss from your baseline weight. The threshold and the periods are on each payer’s page. Put the end date in your calendar and see your prescriber before it, so a current weight is on file.

What each payer’s policy says

Each page below reads one payer’s document in full:

Each page says exactly what its record covers.

What will I pay if my plan covers it?

You pay your plan’s copay or coinsurance (your share of the cost), reduced by a manufacturer savings card if you qualify. If your commercial insurance covers the drug, the cards can lower a fill to as little as $25 for the Wegovy pen, $25 for the Zepbound single-dose pen, $25 for Mounjaro and $25 for Ozempic. Those are “as little as” prices. The manufacturer’s contribution is capped, so a high copay or an unmet deductible can leave you paying more.

The cards are for commercial insurance only. If you’re enrolled in Medicare, Medicaid, TRICARE or another government program, you can’t use them. The savings card guide has the caps and expiry dates.

What if the request is denied?

Read the denial for its reason, because the reason decides what works.

  • Criteria not met or documents missing. This is the fixable kind. Your prescriber can supply what was missing, or you can appeal.
  • Step therapy not satisfied. Show the medicines you’ve already tried, with dates, or the medical reason you can’t take them. FEP Blue’s policy, for example, recognizes “a valid medical exception.”
  • Wrong form. Ask whether the covered form is suitable for you.
  • Excluded benefit. An appeal on clinical grounds doesn’t add a benefit your plan doesn’t have.

Our guide to appealing a GLP-1 denial goes through the steps, and the appeal letter generator drafts the letter in your browser.

What if my plan does not cover weight-loss drugs at all?

You have four routes.

  1. Ask your employer. Several payers leave the decision to the employer, so your benefits team is the one that can change it at renewal.
  2. Ask about other approved uses. If your prescriber is treating a condition the plan covers the drug for, the request belongs under that use.
  3. Use a not-covered offer. Lilly has a separate offer for people whose commercial plan doesn’t cover the Zepbound single-dose pen: $499 a month.
  4. Pay cash. Manufacturer self-pay programs start at $149 a month for Wegovy and $299 for Zepbound. The without-insurance guide and the cheapest path finder compare the routes at your dose.

What about Medicare, Medicaid and TRICARE?

These follow different rules from commercial insurance. By law, Medicare Part D excludes drugs when they’re used for weight loss, and the temporary Medicare GLP-1 Bridge is the route for weight management, at a $50 copay for eligible enrollees. See the Medicare guide. Medicaid coverage depends on your state, and our Medicaid page explains it. TRICARE covers weight-loss GLP-1s on some of its plans, as the TRICARE page sets out.

How to check your own plan in one call

Call the member number on your insurance card and ask:

  1. Does my plan cover medicines for weight management? If not, is it an exclusion?
  2. Is the drug I was prescribed on the formulary, in which form, and on what tier (price level)?
  3. Is prior authorization or step therapy required, and can you send me the written criteria?
  4. How long does an approval last, and what do I need to renew it?

Write down the date, the person’s name and a reference number. Then take the criteria to your prescriber. If the plan covers the drug, the cost calculator shows what a year looks like through each channel.

Frequently asked questions

Is Wegovy covered by insurance for weight loss?

Some plans cover it, with conditions. In the published policies we hold, Aetna, Cigna, FEP Blue and TRICARE allow Wegovy with prior authorization for people who meet their criteria. UnitedHealthcare covers it only where the employer chose the optional program. Blue Cross Blue Shield of Massachusetts excludes it as plans renew from January 1, 2026. Your own plan document decides.

What insurance covers Zepbound?

It varies more than Wegovy does. Highmark's Enhanced policy makes Zepbound the plan-preferred GLP-1, and CVS Caremark returned it to its commercial template formularies on October 1, 2026. FEP Blue and Kaiser Permanente Northwest treat it as non-preferred or non-formulary, with other medicines required first. Several payers also cover it for obstructive sleep apnea.

Why does my insurance cover Ozempic but not Wegovy?

Because plans treat diabetes drugs and weight-loss drugs as separate benefits. In our records, Cigna, Blue Cross Blue Shield of Massachusetts, TRICARE and Anthem's Medi-Cal plan cover Ozempic for type 2 diabetes with a documented diagnosis. Cigna's policy lists weight loss without type 2 diabetes as a use that isn't covered. Wegovy falls under the weight-loss benefit, which many plans leave out.

What BMI do I need for insurance to cover a GLP-1?

It depends on the payer. Cigna, UnitedHealthcare, FEP Blue and Kaiser Permanente Northwest use a BMI of 30 or more, or 27 or more with a weight-related condition. Aetna's policy 6450-C asks for a baseline BMI of 35 or more, and Highmark's Enhanced policy asks for 40 or more plus specified conditions. Each payer page names the policy it reads.

What is prior authorization for a GLP-1?

It's the plan's approval before it will pay. Your prescriber sends a form with your diagnosis, BMI, and the history the policy asks for, such as time in a weight management program. Almost every payer in our records requires it for Wegovy and Zepbound. Our prior authorization page lists the criteria that come up again and again.

What is step therapy?

It's a rule that you must try one or more other medicines first. In our records, FEP Blue asks for at least two oral weight-management medicines before Zepbound, Kaiser Permanente Northwest asks for a 3-month trial of at least two older medicines before Wegovy, and Blue Cross Blue Shield of Michigan applies step therapy to Ozempic and Mounjaro.

Can I use a savings card if my insurance covers the drug?

Yes, if your coverage is commercial. If your plan covers the drug, the manufacturer cards can lower a fill to as little as $25 for Wegovy and $25 for the Zepbound single-dose pen, within the cards' caps. If you're enrolled in Medicare, Medicaid, TRICARE or another government program, you can't use them.

What can I do if my insurance does not cover Wegovy or Zepbound?

First find out whether it's an exclusion or a denial. You can answer a denial for unmet criteria with documents or an appeal. An exclusion means the benefit isn't in your plan. Your routes then are asking your employer to add it, checking whether another approved use applies, or paying cash, which starts at $149 a month for Wegovy and $299 for Zepbound.

Does Medicare cover Wegovy or Zepbound?

Medicare Part D excludes drugs when they're used for weight loss, though it can cover them for other approved uses. From July 1, 2026 through December 31, 2027 the Medicare GLP-1 Bridge gives eligible Part D enrollees certain GLP-1s for weight management for a $50 copay. Our Medicare guide covers the rules.

Sources (24)

  1. 1.
    Aetna: Weight Loss (BMI 35) GIP-GLP-1, GLP-1 Agonists PA with Limit 6450-C P08-2025 v8
    “Authorization may be granted when the requested drug will be used with a reduced-calorie diet AND increased physical activity to reduce excess body weight or maintain weight reduction long term when ALL of the following criteria are met: ... The patient has participated in a comprehensive weight management program that encourages behavioral modification, reduced-calorie diet, AND increased physical activity with continuing follow-up for at least 6 months prior to using drug therapy.”
  2. 2.
    Cigna Healthcare: Weight Loss, Glucagon-Like Peptide-1 Agonists, Wegovy Injection (Coverage Policy Number IP0814, dated 2026-09-01)
    “Prior Authorization is required for benefit coverage of Wegovy injection (Wegovy and Wegovy HD). ... Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months; AND”
  3. 3.
    Cigna Healthcare: Diabetes, Glucagon-Like Peptide-1 Agonists for Employer Plans (Coverage Policy Number IP0701, dated 2026-06-15)
    “Prior Authorization is required for benefit coverage of the GLP-1 agonists and GLP-1/GIP agonist targeted in this policy. ... Diagnosis of Type 2 diabetes mellitus [Documentation Required]”
  4. 4.
    UnitedHealthcare: Prior Authorization/Notification, Weight Loss/Appetite Suppression Medication Coverage (Program Number 2026 P 1114-23, dated 2026-10-01)
    “This is an optional program that is put in place for clients or businesses that have elected to cover weight loss products with Prior Authorization/Notification. ... * Wegovy tablets are typically excluded from coverage.”
  5. 5.
    CVS Caremark: CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options
    “CVS Caremark will add Zepbound back to our commercial formularies as an additional preferred option October 1, 2026, increasing access to GLP-1s at a more affordable price for plan sponsors who elect to provide coverage of those medications for their members.”
  6. 6.
    Blue Cross Blue Shield Federal Employee Program: 5.99.030 Saxenda Wegovy
    “Saxenda and Wegovy may be considered medically necessary if the conditions indicated below are met. ... Patient has participated in a comprehensive weight management program (e.g., Teladoc or another weight loss program)”
  7. 7.
    Blue Cross Blue Shield Federal Employee Program: 5.99.031 Zepbound
    “Zepbound may be considered medically necessary if the conditions indicated below are met. ... the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)”
  8. 8.
    TRICARE: Does TRICARE cover Wegovy, Ozempic, and Mounjaro?
    “TRICARE covers Wegovy, Saxenda, and Zepbound for weight management if you have coverage under one of these plans:”
  9. 9.
    Kaiser Permanente Northwest Region Criteria for Drug Coverage: semaglutide injectable (Wegovy, Wegovy HD)
    “Wegovy injectable is covered under the prescription drug benefit for weight loss ONLY for Kaiser Northwest members with coverage for medications used to treat weight loss. Others pay member cash price.”
  10. 10.
    Kaiser Permanente Northwest Region Criteria for Coverage: tirzepatide (Zepbound)
    “Zepbound is covered under the prescription drug benefit for weight loss ONLY for Kaiser Northwest members with coverage for medications used to treat weight loss. Others pay member cash price. ... Patient has then failed a minimum 6-month trial of semaglutide (Ozempic/Wegovy)”
  11. 11.
    Your 2026 Blue Cross Blue Shield of Michigan and Blue Care Network Preferred Drug List
    “We also don’t cover glucagon-like peptide-agonist drugs used for weight loss, including Saxenda®, Wegovy®, and Zepbound® for commercial members of fully insured large groups and some self-funded groups. ... ZEPBOUND KWIKPEN Not covered QL ZEPBOUND SUBCUTANEOUS SOLUTION AUTO-INJECTOR Preferred brand PA; QL”
  12. 12.
    Blue Cross Blue Shield of Massachusetts: GLP-1 Coverage: Frequently Asked Questions
    “On anniversary, starting January 1, 2026, Wegovy, Saxenda, and Zepbound will be excluded from coverage. ... Employer groups with more than 100 employees have the option of adding coverage for weight-loss drugs for an additional cost.”
  13. 13.
    Highmark Pharmacy Policy Bulletin: J-1388 Anti-Obesity (Enhanced), Commercial and Healthcare Reform (Version J-1388-028, dated 2026-07-01)
    “When a benefit, initiation of Saxenda (liraglutide), Foundayo, Wegovy, or Zepbound may be approved when all of the following criteria are met (1. through 8.): ... contraindication (specifically, documented allergic reaction, hypersensitivity) to plan-preferred Zepbound.”
  14. 14.
    Anthem Blue Cross (California Medi-Cal): GLP-1 Coverage Considerations
    “Effective January 1, 2026, these drugs will be removed from the CDL and will no longer be eligible for coverage for weight loss or weight-loss indications:”
  15. 15.
    Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
    “The statutory definition of a covered Part D drug at section 1860D-2(e)(2) of the Social Security Act (the Act) excludes certain drugs and uses—specifically, those that may be excluded by Medicaid under section 1927(d)(2) of the Act. This includes, at section 1927(d)(2)(A) of the Act, “agents when used for anorexia, weight loss, or weight gain.” Historically, drugs used for weight loss have been excluded from the definition of covered Part D drug, regardless of their use for treatment of individuals with obesity, and have been an optional drug benefit for Medicaid programs.”
  16. 16.
    CMS: Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (CMS-4208-P)
    “Since the inception of the Part D program, CMS has interpreted the statutory exclusion of “agents when used for weight loss” to mean that a drug, when used for weight loss, is excluded from the definition of a covered Part D drug. This historical interpretation does not distinguish between use of a drug for treatment of individuals with obesity and individuals without obesity. Therefore, under current policy, anti-obesity medications are only coverable in Part D if the drug is being used to treat another condition that is a medically accepted indication other than weight loss or weight management (for example, type 2 diabetes or to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight).”
  17. 17.
    Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
    “Currently, state Medicaid programs have discretion to cover the drugs or classes of drugs listed in section 1927(d)(2) of the Act, including “agents used for . . . weight loss . . .””
  18. 18.
  19. 19.
  20. 20.
  21. 21.
  22. 22.
  23. 23.
  24. 24.